Yahoo · Nov 4, 2026
LivaNova PLC Q3 2026 Earnings Call Summary
Moby summary of LivaNova PLC's Q3 2026 earnings call
NASDAQ · TMO
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$706.16
Up+$7.82 (+1.12%)
Updated Nov 5, 2026, 5:59 AM
SID Score
6.8/10
Composite research score
Smart Money
45/100
Neutral
- Market cap
- 219.39B
- P/E ratio
- 33.3
- Dividend yield
- 0.30%
- 52-week range
- $435.27 – $712.17
- Volume
- 2.46M
- Avg. volume
- 2.05M
Price performance · TMO
TMO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
TMO closed at $706.16 after 21 trading sessions, up 6.66% for the selected period.
- Last close
- $706.16
- Period change
- +6.66%
- Period low
- $651.98
- Period high
- $709.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $708.00 | $712.1723 | $691.96 | $706.16 | 2.46M |
| Nov 3, 2026 | $677.92 | $700.20 | $671.9946 | $698.34 | 1.65M |
| Nov 2, 2026 | $699.86 | $699.86 | $679.40 | $682.65 | 1.85M |
| Oct 30, 2026 | $710.69 | $711.79 | $691.74 | $697.00 | 2.09M |
| Oct 29, 2026 | $703.575 | $711.8545 | $699.90 | $709.18 | 1.47M |
| Oct 28, 2026 | $691.83 | $710.84 | $691.0302 | $704.15 | 1.65M |
| Oct 27, 2026 | $680.96 | $700.99 | $676.00 | $693.02 | 1.83M |
| Oct 26, 2026 | $675.855 | $685.48 | $674.37 | $684.89 | 1.95M |
| Oct 23, 2026 | $672.69 | $677.28 | $662.5025 | $673.82 | 2.04M |
| Oct 22, 2026 | $691.70 | $703.20 | $674.10 | $676.54 | 3.6M |
| Oct 21, 2026 | $665.00 | $705.785 | $661.30 | $694.02 | 4.05M |
| Oct 20, 2026 | $680.17 | $693.365 | $679.32 | $687.37 | 3.53M |
| Oct 19, 2026 | $691.31 | $692.99 | $673.47 | $679.38 | 2.4M |
| Oct 16, 2026 | $692.26 | $699.20 | $683.63 | $690.00 | 2.11M |
| Oct 15, 2026 | $686.13 | $704.00 | $671.47 | $696.49 | 3.96M |
| Oct 14, 2026 | $664.01 | $681.50 | $659.00 | $673.20 | 2.49M |
| Oct 13, 2026 | $662.84 | $666.38 | $655.73 | $663.04 | 2.3M |
| Oct 12, 2026 | $657.23 | $662.54 | $652.5001 | $662.24 | 1.38M |
| Oct 9, 2026 | $650.00 | $661.94 | $644.1605 | $658.02 | 1.58M |
| Oct 8, 2026 | $657.53 | $658.56 | $635.32 | $651.98 | 2.59M |
| Oct 7, 2026 | $662.40 | $671.665 | $651.12 | $662.06 | 1.83M |
Latest TMO news
The latest Smart Investors Daily articles mentioning TMO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TMO research
Overview
Company profile and research snapshot.
Company profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $625.78
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Argus Research | Buy | — |
| Oct 23, 2026 | Citigroup | Buy | — |
| Oct 22, 2026 | TD Cowen | Buy | — |
| Oct 22, 2026 | Stifel | Buy | — |
| Oct 22, 2026 | Baird | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 4, 2026
Guidance Up, Trend Intact: Mettler-Toledo Is Today's Double-Confirmation Stock
For questions about this article or underlying research, email [email protected].
Yahoo · Nov 4, 2026
Microcarriers - Global Strategic Business Report 2026: Secure Your Share of $3.9 Billion by 2032 | Benchmark Corning, Danaher, Sartorius, and Thermo Fisher
Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Microcarriers - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global microcarriers market was valued at US$2.3 billion in 2025 and is projected to reach US$3.9 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.5%. Market growth is supported by increasing biologics production, advances in cell and gene therapy, expanding vaccine manufacturing capacity, and sustained investment in biotechn
Yahoo · Nov 4, 2026
Thermo Fisher (TMO) Emerges as Top Contributor After 27% Quarterly Gain
BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its third-quarter 2026 investor letter for “Buffalo Growth Fund”. The letter can be downloaded here. The Buffalo Growth Fund advanced 4.57% in Q3, significantly outperforming the Russell 3000® Growth Index’s 0.45%. The primary driver of this outperformance was stock selection in Information […]
AI research layers
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $698.34, declining 1.05% in the most recent session, per SID market data. Despite the daily pullback, the stock has demonstrated positive momentum across multiple timeframes, gaining 4.25% over the past month, 20.88% over the trailing three months, and 10.61% year-over-year. The stock trades well above key moving averages, sitting 6.50% above its 50-day moving average of $655.71 and 28.31% above its 200-day moving average of $544.31, according to Massive/Polygon technical data. The 14-day relative strength index registers at 56.7, indicating neutral momentum without overbought or oversold conditions. Thermo Fisher carries a beta of 0.902, reflecting slightly lower volatility than the broader market. Average daily trading volume stands at approximately 2.05 million shares, supporting consistent liquidity for institutional and retail participants. The company maintains a market capitalization of approximately $219.4 billion.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific Inc. currently trades at a price-to-earnings ratio of 33.30, positioning it at a premium relative to the broader Healthcare sector, per SID market data. The company's price-to-book ratio stands at 4.29, reflecting the market's valuation of intangible assets including its extensive intellectual property portfolio and brand value. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple is not supported by near-term earnings growth expectations, according to SEC filings. Thermo Fisher offers a modest dividend yield of 0.29%, consistent with the company's capital allocation strategy that historically prioritizes reinvestment and acquisitions over shareholder distributions. With a market capitalization of $219.4 billion, Thermo Fisher remains one of the largest pure-play life sciences companies globally. Investors appear willing to pay a premium valuation for the company's diversified revenue streams and dominant market positioning across laboratory equipment, diagnostics, and specialty chemicals.
Smart Money Activity for TMO
Thermo Fisher Scientific Inc. registers a composite smart money score of 46, signaling a neutral overall positioning among sophisticated market participants, per SID market data. Institutional ownership receives a perfect score of 25 out of 25, indicating exceptionally strong conviction from large asset managers and pension funds. However, insider activity scores a more moderate 9.4 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales. The sell-to-buy ratio of roughly 2.3-to-1 reflects net insider disposition, though such activity can reflect routine diversification rather than bearish sentiment. Dark pool activity scores 8.5 out of 25, suggesting below-average institutional accumulation through off-exchange venues. Congressional trading activity registers at just 3.2 out of 25, according to disclosure filings, indicating minimal legislative interest in the stock. The divergence between strong institutional holdings and moderate insider confidence warrants monitoring as a potential signal of near-term directional uncertainty.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific Inc. has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $6.68 against a consensus estimate of $6.40, representing a positive surprise of $0.28 or 4.38%. The prior quarter saw EPS of $6.03 versus the $5.71 estimate, a beat of $0.32 or 5.60%, while the quarter before that produced EPS of $5.44 compared to the $5.23 estimate, a $0.21 upside surprise. The sequential earnings trajectory from $5.44 to $6.03 to $6.68 demonstrates accelerating profitability across the three reported periods. Looking ahead, analyst estimates project EPS of $5.71 for the upcoming reporting period scheduled for July 2026. The consistent pattern of exceeding Wall Street expectations by an average of $0.27 per quarter underscores management's track record of conservative guidance and operational execution.
Wall Street Analyst Ratings for TMO
Wall Street consensus on Thermo Fisher Scientific Inc. remains unanimously bullish, with all five most recent analyst actions reaffirming positive ratings, according to Wall Street analyst reports. On October 30, 2026, Argus Research maintained its Buy rating, followed by Citigroup reiterating Buy on October 23. Both TD Cowen and Stifel reiterated Buy ratings on October 22, while Baird maintained its Outperform rating on the same date. Notably, none of the recent analyst actions involved upgrades or downgrades, as each firm carried forward its prior bullish stance, per SID consensus data. The clustering of reaffirmations around late October aligns with the company's most recent earnings release on October 21, where Thermo Fisher beat estimates by $0.28 per share. The absence of any Hold or Sell ratings among recent coverage updates reflects broad institutional confidence in the company's competitive positioning within the life sciences tools and diagnostics markets. No analyst downgrades have been recorded in the current review period.
